GlassScriptPhysician profile
Nader G Iskander
NPI 1659369601
$12,445.76
in general payments reported to CMS, 2019-2025
32 companies · $936 in 2025
The $936 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,720 · 2020: $250 · 2021: $682 · 2022: $872 · 2023: $2,811 · 2024: $3,174 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,896 · Consulting Fee: $3,000 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,895.79 |
| Consulting Fee | $3,000.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $3,402.09 | 2021-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $1,906.11 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Alcon Vision LLC | $919.09 | 2019-2025 | Centurion, Hydrus Microstent, Clareon |
| Biotissue Holdings INC. | $900.77 | 2020-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $887.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $533.62 | 2019-2023 | |
| Abbvie INC. | $509.32 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $484.32 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $473.16 | 2019-2025 | Cequa, Xelpros |
| Allergan, INC. | $288.08 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $266.85 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $241.62 | 2019-2022 | |
| Ocular Therapeutix, INC. | $175.02 | 2020-2023 | Dextenza |
| Shire North American Group INC | $167.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $124.99 | 2021 | |
| Carl Zeiss Meditec, INC. | $120.00 | 2019 | |
| Lensar, INC. | $118.70 | 2019-2023 | Lensar Laser System |
| Pacira Pharmaceuticals Incorporated | $112.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $108.77 | 2024-2025 | Acthar |
| Horizon Therapeutics Plc | $108.39 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $79.00 | 2023-2025 | Tyrvaya, Ryzumvi |
| Staar Surgical Company | $75.36 | 2019 | |
| Rayner Intraocular Lenses Limited | $62.45 | 2022-2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Omeros Corporation | $53.70 | 2021 | |
| Dompe US, INC. | $51.20 | 2019-2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $50.97 | 2023 | Visumax |
| Thea Pharma INC. | $24.53 | 2023 | |
| Aerie Pharmaceuticals, INC. | $20.79 | 2021 | |
| New World Medical,INC. | $19.66 | 2024 | Kahook Dual Blade, Clearpath, Streamline |
| Harrow Eye, LLC | $18.22 | 2025 | |
| Tearlab Corp | $15.48 | 2023 | Tearlab Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Iskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.